NCT02239237已完成不适用
Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study
Zhong Wang29 个研究点 分布在 1 个国家目标入组 30,283 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30,283
- 试验地点
- 29
- 主要终点
- The incidence of severe adverse reactions (SAR) to the Compound Kuh-seng Injection
研究概览
简要总结
This registry aims to monitor the safety of Compound Kuh-seng Injection and to identify the potential risk factors for the adverse drug reactions. Compound Kuh-seng Injection is a kind of natural compound injection extracted from herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who use Compound Kushen Injection in the monitoring hospitals
排除标准
- 未提供
研究组 & 干预措施
Compound Kuh-seng Injection
Compound Kuh-seng Injection will be given to the patients, and the investigators will record all the information including ADR, application of Compound Kuh-seng Injection and the combined medications, etc.
干预措施: Compound Kuh-seng Injection (Drug)
结局指标
主要结局
The incidence of severe adverse reactions (SAR) to the Compound Kuh-seng Injection
时间窗: 2 years
次要结局
- The incidence of anaphylactic reaction to Compound Kuh-seng Injection(2 years)
- The incidence of new ADRs to Compound Kuh-seng Injection(2 years)
- The incidence of new SARs to Compound Kuh-seng Injection(2 years)
- The incidence of adverse drug reactions (ADR) to Compound Kuh-seng Injection(2 years)
研究者
Zhong Wang
Dr
China Academy of Chinese Medical Sciences
研究点 (29)
Loading locations...
相似试验
Unknown
不适用
Post-marketing Safety Surveillance of Xueshuantong-Injection : a Registry StudyAdverse Drug EventAdverse Drug ReactionsAnaphylactic ReactionSevere Adverse ReactionsNCT03640884Zhong Wang30,000
招募中
不适用
Post-marketing Safety Surveillance of Qizhi Tongluo Capsules:a Registry Study.Safety SurveillanceAdverse Drug EventsAdverse Drug ReactionsSevere Adverse EventsSevere Adverse ReactionsNCT04479553Zhong Wang30,000
暂停
不适用
Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry StudyAdverse Drug EventAdverse Drug ReactionChinese MedicineAnaphylactic ReactionNCT02559960Zhong Wang20,000
已完成
不适用
A Study of Fycompa (Perampanel) in Korean ParticipantsEpilepsyNCT02722590Eisai Korea Inc.3,692
已完成
不适用
Prevenar13 Post Market SurveillanceHealthyNCT01509105Pfizer649